Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-573 + AI in HR+/HER2- Metastatic Breast Cancer
NCT01446159Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jun 2011
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of dusigitumab in breast cancer, sponsored by MedImmune. Started Jun 2011; status: completed.
02
Drugs
dusigitumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01446159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01446159.